OptiBiotix Health PLC Director/PDMR Shareholding (0842W)
21 Aprile 2021 - 8:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0842W
OptiBiotix Health PLC
21 April 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Director and PDMR Dealings
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces that it received
notification on 20 April 2021 of the following purchases made by
Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René
Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:
Name Number Purchase Number of Resulting % of issued
of shares price shares held shareholding share capital
purchased prior to purchase
Stephen O'Hara 47,857 53.0p 10,165,129 10,212,986 11.61
----------- --------- ------------------- -------------- ---------------
René Kamminga 35,000 52.4p Nil 35,000 0.04
----------- --------- ------------------- -------------- ---------------
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
-----------------------------------------------------------------------------------------------
a. Name a) Stephen O'Hara
b) René Kamminga
-------------------------------------- -------------------------------------------------------
2 Reason for notification
-------------------------------------- -------------------------------------------------------
a. Position/Status a) Chief Executive Officer
b) PDMR
-------------------------------------- -------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
-------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
-------------------------------------- -------------------------------------------------------
b. LEI 213800UKYQFT941QHS14
-------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------------------------
a. Description of Ordinary shares of 2p each
the financial
instrument, type
of instrument ISIN: GB00BP0RTP38
Identification
Code
-------------------------------------- -------------------------------------------------------
b. Nature of the Purchase of ordinary shares in the Company
transaction
-------------------------------------- -------------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
-------------------------------------- ------------------------
a) 53.0p a) 47,857
b) 52.4p b) 35,000
------------------------ -------------------
d. Aggregated information
* Volume n/a
* Price
-------------------------------------- -------------------------------------------------------
e. Date of the transaction 20 April 2021
-------------------------------------- -------------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
-------------------------------------- -------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSELFMSEFSEFL
(END) Dow Jones Newswires
April 21, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Apr 2023 a Apr 2024
